AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin

@inproceedings{Rosen2013AKTSA,
  title={AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin},
  author={David B. Rosen and Kimberly H. Harrington and James A. Cordeiro and Ling Yan Leung and Santosh Putta and Norman J. Lacayo and George S. Laszlo and Chelsea J. Gudgeon and Donna Hogge and Rachael Elizabeth Hawtin and Alessandra Cesano and Roland B Walter},
  booktitle={PloS one},
  year={2013}
}
Gemtuzumab ozogamicin (GO), an immunoconjugate between an anti-CD33 antibody and a calicheamicin-γ(1) derivative, induces remissions and improves survival in a subset of patients with acute myeloid leukemia (AML). As the mechanisms underlying GO and calicheamicin-γ(1) resistance are incompletely understood, we herein used flow cytometry-based single cell network profiling (SCNP) assays to study cellular responses of primary human AML cells to GO. Our data indicate that the extent of DNA damage… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Antibody-targeted drugs and drug resistance--challenges and solutions.

  • Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND

Targeting PI3K/AKT/mTOR network for treatment of leukemia

  • Cellular and Molecular Life Sciences
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND

Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia

  • International Journal of Hematology
  • 2013
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 45 REFERENCES

Technology evaluation: Valspodar, Novartis AG.

  • Current opinion in molecular therapeutics
  • 2000
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
VIEW 2 EXCERPTS

Similar Papers